Nasdaq:US$18.12 (-0.52) | HKEX:HK$28.75 (-0.90) | AIM:£2.93 (-0.03)
上一篇文章   |   下一篇文章
公告及新闻稿, 监管通知 | 2015-10-30

Total Voting Rights

London: Friday, 30 October 2015: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) hereby notifies the market that as at 30 October 2015, the issued share capital of Chi-Med consisted of 56,533,118 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 56,533,118 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority’s Disclosure Rules and Transparency Rules.




Telephone:      +852 2121 8200
Christian Hogg, CEO


Panmure Gordon (UK) Limited
Telephone:      +44 20 7886 2500
Richard Gray
Andrew Potts


Citigate Dewe Rogerson
Telephone:      +44 20 7638 9571
Anthony Carlisle
Mobile:            +44 7973 611 888
David Dible
Mobile:            +44 7967 566 919


About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: